{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:49:52Z","timestamp":1794372592367,"version":"4.9.0"},"reference-count":63,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:p>Antitumor necrosis factor \u03b1 (anti-TNF) agents have dramatically influenced management of refractory inflammatory bowel disease (IBD). However, not all patients respond to treatment and some lose response or become intolerant over time. Immunogenicity, a well established phenomenon with anti-TNF agents, may have important clinical implications in patients with IBD. A comprehensive review of available evidence demonstrating how drug concentrations, immunogenicity, and other factors influence outcomes with anti-TNF agents was performed. PubMed, EMBASE, Biosis, Dialog, and Conference Papers Index were searched from 1 January 1995 to 7 April 2012 to identify clinical trials in adult and pediatric patients with IBD treated with anti-TNF agents for Crohn\u2019s disease or ulcerative colitis. Data on serum drug levels and immunogenicity and their relationship with clinical efficacy and safety outcomes were extracted and examined. Serum infliximab concentrations correlated with clinical efficacy and treatment outcomes in patients with IBD; this relationship is less well characterized with adalimumab and certolizumab pegol concentrations. In multiple studies, the presence and level of antibodies to infliximab correlated with loss of clinical efficacy and increased risk of infusion reactions. The incidence and clinical impact of antibody formation with adalimumab or certolizumab in IBD is becoming evident as more data become available. Current, enzyme-linked immunosorbent assay based anti-TNF antibody assays are suboptimal in that results are often inconclusive and comparisons between agents cannot be made. Measurement of anti-TNF agent drug concentrations and assessment of immunogenicity has the potential to positively impact clinical decision making during anti-TNF therapy for IBD. As assays are optimized, it is expected that the clinical impact of these determinations will be better characterized.<\/jats:p>","DOI":"10.1177\/1756283x13479826","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:51:48Z","timestamp":1362703908000},"page":"269-293","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":75,"title":["Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response"],"prefix":"10.1177","volume":"6","author":[{"given":"Gary R.","family":"Lichtenstein","sequence":"first","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Perelman School of Medicine of the University of Pennsylvania, Department of Medicine, Gastroenterology Division, Hospital of the University of Pennsylvania, 9th Floor Penn Tower, One Convention Center, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.9"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01638.x"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.005"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/nano.2007.2.1.3"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.01.015"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)61471-1"},{"key":"e_1_3_3_9_1","first-page":"77","article-title":"Biologic targeting in the treatment of inflammatory bowel diseases","volume":"3","author":"Bosani M.","year":"2009","unstructured":"Bosani M., Ardizzone S., Porro G. B. (2009) Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 3: 77\u201397.","journal-title":"Biologics"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/2031352a0"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90398-0"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.01.019"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.07.010"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20899"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21831"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_3_3_18_1","unstructured":"Crohn\u2019s & Colitis Foundation of America (2007) Living with Crohn\u2019s disease. Available at: http:\/\/www.ccfa.org\/about\/press\/ibdfacts (accessed 9 September 2011)."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/nano.2007.2.1.39"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(11)61176-1"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.06.002"},{"key":"e_1_3_3_23_1","volume-title":"Presented at 2012 Digestive Disease Week","author":"Feagan B","year":"2012","unstructured":"Feagan B, Singh S., Lockton S., Hauenstein S., Ohrmund L., Greenberg G., et al. (2012) Novel infliximab (IFX) & antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn\u2019s disease (CD) [abstract 565]. Presented at 2012 Digestive Disease Week, 19\u201322 May 2012, San Diego, CA, USA."},{"key":"e_1_3_3_24_1","volume-title":"Presented at the Annual United European Gastroenterology Week","author":"Ferrante M","year":"2011","unstructured":"Ferrante M, Karmiris K., Compernolle G., Ballet V., Vermeire S., Noman M., et al. (2011) Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome [abstract OP312]. Presented at the Annual United European Gastroenterology Week, 22\u201326 October 2011, Stockholm, Sweden."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464160-00004"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20036"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.07.062"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/11531280-000000000-00000"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90054-X"},{"key":"e_1_3_3_34_1","first-page":"S101","article-title":"Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn\u2019s disease in classic I and II [abstract 741]","volume":"142","author":"Li J.","year":"2012","unstructured":"Li J., Paulson S., Chiu Y., Robinson A., Lomax K., Pollack P. (2012) Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn\u2019s disease in classic I and II [abstract 741]. Gastroenterology 142: S101.","journal-title":"Gastroenterology"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04027.x"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.01.014"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.06.025"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200405000-00008"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03734.x"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530560-000000000-00000"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365529509096316"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.12.1705"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20225"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.12.1.181"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)60431-4"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50182"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.04.021"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31072"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)62167-2"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.03.024"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.183095"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.42"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03638-X"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.004"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9946(12)60273-6"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)60428-4"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099978"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03828.x"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X13479826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756283X13479826","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X13479826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:39:22Z","timestamp":1790167162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756283X13479826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,7]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1177\/1756283X13479826"],"URL":"https:\/\/doi.org\/10.1177\/1756283x13479826","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,7]]}}}